Article

One-site approach is an option for cataract-trabeculectomy

Anaheim, CA-The one- and two-site cataract-trabeculectomy combined procedures eachhave unique advantages and disadvantages for treating patients with cataract and glaucoma (See Page 74). Richard A. Lewis, MD, described the one-site approach at the American Academy of Ophthalmology annual meeting.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
(Image credit: AdobeStock/matucha12) NASA scientist Steven Laurie, PhD, on extreme telemedicine during long-duration spaceflight
June 14th 2025

NASA scientist Steven Laurie, PhD, on extreme telemedicine during long-duration spaceflight

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Resident surgeons perform ISBCS with similar safety and accuracy as consultants
June 13th 2025

Resident surgeons perform ISBCS with similar safety and accuracy as consultants

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation
June 12th 2025

FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation

HIV drug lamivudine shows promise in treating diabetic macular edema
June 12th 2025

HIV drug lamivudine shows promise in treating diabetic macular edema

© 2025 MJH Life Sciences

All rights reserved.